ABUS
Price
$2.74
Change
+$0.10 (+3.79%)
Updated
Apr 23, 6:59 PM EST
8 days until earnings call
INO
Price
$10.37
Change
+$0.35 (+3.49%)
Updated
Apr 23, 6:59 PM EST
15 days until earnings call
Ad is loading...

Compare trend and price ABUS vs INO

Header iconABUS vs INO Comparison
Open Charts ABUS vs INOBanner chart's image
Arbutus Biopharma
Price$2.74
Change+$0.10 (+3.79%)
Volume$730.57K
CapitalizationN/A
Inovio Pharmaceuticals
Price$10.37
Change+$0.35 (+3.49%)
Volume$132.35K
CapitalizationN/A
View a ticker or compare two or three
ABUS vs INO Comparison Chart

Loading...

ABUSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
INODaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ABUS vs. INO commentary
Apr 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and INO is a Hold.

COMPARISON
Comparison
Apr 24, 2024
Stock price -- (ABUS: $2.64 vs. INO: $10.02)
Brand notoriety: ABUS: Not notable vs. INO: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 55% vs. INO: 66%
Market capitalization -- ABUS: $495.48M vs. INO: $259.07M
ABUS [@Biotechnology] is valued at $495.48M. INO’s [@Biotechnology] market capitalization is $259.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $557.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.53B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileINO’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • INO’s FA Score: 0 green, 5 red.
According to our system of comparison, ABUS is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 2 TA indicator(s) are bullish while INO’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 2 bullish, 7 bearish.
  • INO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, INO is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а -11.11% price change this week, while INO (@Biotechnology) price change was -8.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.03%. For the same industry, the average monthly price growth was +4.97%, and the average quarterly price growth was +1257.50%.

Reported Earning Dates

ABUS is expected to report earnings on Aug 01, 2024.

INO is expected to report earnings on May 08, 2024.

Industries' Descriptions

@Biotechnology (+10.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ABUS with price predictions.
OPEN
A.I.dvisor published
a Summary for INO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ABUS($495M) has a higher market cap than INO($259M). INO YTD gains are higher at: 63.726 vs. ABUS (5.600).
ABUSINOABUS / INO
Capitalization495M259M191%
EBITDAN/AN/A-
Gain YTD5.60063.7269%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
ABUS vs INO: Fundamental Ratings
ABUS
INO
OUTLOOK RATING
1..100
8767
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
4243
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (54) in the Biotechnology industry is in the same range as INO (68) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

ABUS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

ABUS's SMR Rating (97) in the Biotechnology industry is in the same range as INO (98) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

ABUS's Price Growth Rating (42) in the Biotechnology industry is in the same range as INO (43) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

ABUS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that ABUS’s stock grew similarly to INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSINO
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 27 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
ABUSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
INODaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SSAQX73.540.67
+0.92%
State Street US Core Equity Fund
VYSVX20.270.16
+0.80%
Vericimetry US Small Cap Value
PWDIX8.680.05
+0.58%
Donoghue Forlines Dividend I
FGJMX93.810.54
+0.58%
Fidelity Advisor Communication ServicesI
MNBWX18.720.09
+0.48%
Manning & Napier Pro-Blend Extnd Term W